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Cyclic sulfamides are attractive molecules with potential application in medical chemistry. It is 
known that thiadiazepine-containing derivatives demonstrate promising value in the development of 
protease inhibitors such as HIV protease, serine protease and metaloprotease. We demonstrate here 
a comfortable synthetic sequence to symmetric thiadiazepines containing isoxazole substitutents. 
The structure of the obtained substances was confirmed by 1H, 13C NMR spectroscopy. 
________________________________________________________________________________ 
Introduction 
One of the most famous classes of 
synthetic bacteriostatic antibiotics that are 
widely used in medicine are sulfamides. A large 
number of substances of this type became well-
known drugs such as streptocide [1], furacemide 
[2], amprenavir [3], E7070 [4], sulfatiazole [1], 
acetozolamide [5], and others. Recently, the 
ability of the sulfamide fragment to inhibit some 
classes of enzymes that affect various 
physiological processes has been discovered. 
This facilitated the development of drugs for the 
treatment of glaucoma [6], epilepsy [7], arthritis 
[8], osteoporosis [9], Alzheimer's disease [10], 
cancer [11], and others. Cyclic sulfamides  are 
very important scaffolds both in medicinal 
chemistry and in synthetic organic chemistry 
[12], among of them, have been found 
substances that have proven themselves as 
peptidomimetics, in particular, HIV-proteinase 
inhibitors [13], [14]. Thus, in particular, N, N'-
disubstituted derivatives of thiodiazepines were 
active inhibitors of HIV-1 proteinase [15], [16]. 
A number of substances of this type have been 
patented as anti-HIV agents [17]. Taking into 
account the need for a constant search for new 
potentially biologically active substances and a 
variety of biological activity of the isoxazole  
Derivative,[18], [19], [20], [21] we 
offered a way of obtaining new isoxazole-
containing derivatives of thiodiazepines using as 
key stage of the synthesis ring closing 
metathesis reactions [22], [23]. 
Results and Discussion 
 One of the advantages of this strategy 
is the formation in the process of obtaining a 
cycles with double bonds, which if necessary 
could be used to introduce into the seven-
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membered cycle of the necessary 
pharmacophore groups. Using this strategy, we 
have obtained several new symmetric 
isooxazole-containing thiadiazepines.   
 As starting compounds for achieving 
the stated goal, we have used, as described in 
the literature (2a-b) [24], and as new 3-
substituted-5-aminomethyl isoxazoles (2 c-d) 
[25], which have been synthesized from the 
previously described brominated derivatives(1a-
b ) [26],  by the method of Delepin (Scheme 1). 
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Scheme 1. Synthesis 3-substituted-5-aminomethyl isoxazoles and corresponding sulfamides. 
A series of new sulfamides (3 a-d) was 
synthesized by the interaction of amine 
hydrochlorides (2 a-d) with sulfuryl chloride in 
the presence of triethylamine. Acylation of 
amines with sulfuryl chloride was carried out in 
solutions of dichloromethane at a temperature of 
about 0 oC for 1.5-2 hours. Target products (3 a-
d) were obtained with 66-76 % yields. The 
structure of obtained compounds is confirmed 
by the data of chromatomas spectra, 1H, 13C 
NMR spectra and elemental analysis. 
Sulfonylamides (3 a-d) were alkylated 
on two amide nitrogen atoms with 2.2 
equivalents of allyl bromide (10 % excess) in 
DMF solutions at a temperature of 64-75 oC in 
the presence of a 2.3 equivalents of potassium 
carbonate (15 % excess) (Scheme 2). 
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Scheme 2. Synthesis diallyl containing sulfamides and corresponding isoxasole containing derivatives of thiadiazepine. 
Diallyl derivatives (4a-d) were isolated 
with 73-81% yields. Their structure is 
confirmed by chromatomass spectra, elemental 
analysis and data of 1H, 13C NMR spetra. Ring-
closing metathesis reactions of the derivative 
(4a-d) were carried our in solutions of dry 
degassed dichloromethane  in the atmosphere of 
dry argon at a temperature of 25-30 oC for 10-12 
hours using a ruthenium-carbene catalyst ([Ru]) 
(Scheme 2). The products (5a-d) were isolated 
after chromatographic purification with 74-85 % 
yields. Their structure is confirmed by 
chromatomass spectra, elemental analysis and 
data of 1H, 13C NMR spectra, elemental 
analysis. The disappearance  of the signals of 
four protons of terminal =CH2- groups in the 
region of 5.33 ppm and two allilic –CH= groups 
in the 5.8 ppm that are present in the spectra of 
the starting compounds (4a-d), as well as the 
appearance of the specific signal at the 4.6 ppm 
indicates the formation of thiadiazepine ring. In 
the 13C  NMR spetra of each of the compounds 
(5a-d), there is a signal of C atoms at 127.7 
ppm, characteric of the sp2 hybridized carbon 
atoms of the seven-membered ring, and there is  
no signal of the  carbon atoms of the terminal 
=CH2-groups at 120.7 ppm, observed in the 
spectra of the starting diallyl derivatives (4a-d).  
 
Experimental part 
General information: 1H 1H (500 MHz) 
and 13C (125 MHz) NMR spectra were 
recorded on Bruker Avance DRX 500 
spectrometer in CDCl3, DMSO–d6 solution 
with TMS. Chromatomass spectra were 
recorded using a liquid chromatography-mass 
spectrometric system using an Agilent 1100 
Series high performance liquid chromatograph 
equipped with a diode array with an Agilent 
LC/MSD SL mass-selective detector (ionization 
method - is the chemical ionization at 
atmospheric pressure, APCI). Parameters of 
chromatography-mass analysis: column-Zorbax 
SB-C18, 1.8 µm, 4.6 х 15 mm; solvents A) 
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MeCN-H2O 95: 5, 0,1% aqueous CF3COOH, B) 
0,1% aqueous CF3COOH; flow eluent – 3 ml / 
min; Injection volume – 1 µm; UV detectors- 
215, 254, 285 nm; Cl at atmospheric pressure. 
Elemental analysis was carried out in the 
laboratory of analytical chemistry of the 
Institute of Bioorganic Chemistry and 
Petrochemistry of the National Academy of 
Sciences of Ukraine: the carbon and hydrogen 
content was determined by the weight method 
of Pregle, nitrogen by the Dumas gas meterind 
method, and chlorine by the mercuric method. 
For column chromatography, was used silica gel 
Merck Grade 9385, 60 A, 230-400. The 
commercially available reagents and solvents, 
were used for this work, bromine derivatives of 
isoxazoles (3 a-g) were synthesized by the 
procedure [26]. 
 {[3- (4-ethoxyphenyl) isoxazol-5-yl] 
methyl} amine hydrochloride (2c) Colourless 
solid (45 % yield); Mp: 221-222 oC.  1H NMR 
(500 MHz,  DMSO-d6): δ = 1.34 (t, J= 8.5 Hz, 
3H), 4.06 (k, J=8.5 Hz, 4H), 4.28 ( s, 4H), 7.05 
(d, J= 10.5 Hz, 2H), 7.10 (s, 1H), 7.76 (d, 
J=10.5 Hz, 2H), 8.90 ( s, 3H).   13C NMR (125 
MHz, DMSO-d6, ppm): δ = 15.0, 34.3, 63.7, 
102.9, 115.5, 120.7, 128.5, 160.6, 162.1, 166.5 
ppm; MS (Cl): m/z 255 (MH+ 100). Anal calcd. 
for C12H15ClN2O2: C, 56.58, H, 5.94, Cl, 13.92, 
N, 11.00. Found: C, 56.55, H, 5.96, Cl, 13.90 N, 
11.04. 
{[3-(4-propoxyphenyl) isoxazol-5-yl] 
methyl} amine hydrochloride (2d) Colourless 
solid (39% yield); Mp: 199-201 oC.  1H NMR 
(500 MHz, DMSO-d6): δ = 0.98 (t, J= 9.0 Hz, 
3H), 1.69-1.80 (m, 2H), 3.98 (t, J=8.0 Hz, 2H), 
4.28 ( s, 4H), 7.06 (d, J= 10.5 Hz, 2H), 7.12 (s, 
1H), 7.76 (d, J=10.5 Hz, 2H), 8. ( s, 3H).   13C 
NMR (125 MHz, DMSO-d6, ppm): δ = 8.3, 
19.9, 31.9, 67.1, 100.4, 113.1, 118.3, 126.1, 
158.3, 159.6, 164.0 ppm; MS (Cl): m/z 269 
(MH+ 100). Anal calcd. for C13H17ClN2O2: C, 
56.58, H, 6.38, Cl, 13.19, N, 10.42. Found: C, 
56.56, H, 6.40, Cl, 13.20 N, 11.89. 
 
General procedure for the synthesis of 
for N,N'-bis[(3-arylisoxazol-5-
yl)methyl]sulfamides: Solution ( 0,01 mol) of 
sulfuryl chloride in dichloromethane was added 
slowly to a solution of isoxazole-containing 
amine hydrochlorides (g, 0.02 mol) in 30 ml 
dichloromethane at -5-0 ° C in the presence of 
(g, 0.04 mol) triethylamine for 1.5-2 hours. 
After adding all sulfuryl chloride, the reaction 
mixture is stirred for 1.5-2 hours at room 
temperature. After completion of the reaction, 
the mixture was filtered off, the solvent was 
evaporated in vacuo, residue was washed with 
water (2 x 20 ml). Target products were purified 
by recrystallization from 96% ethanol. 
N,N'-bis[(3-phenylisoxazol-5-
yl)methyl]sulfamide (3a) Colourless solid (83% 
yield); Mp: 165-166 oC.  1H NMR (500 MHz, 
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DMSO-d6): δ = 4.31-4.35 (br. S, 4H), 6.82-6.97 
(br. S, 2H), 7.43-7.57 (m. 6H), 7.75-7.88 (m, 
4H), 7.88-7.99 (m, 2H). 13C NMR (125 MHz, 
DMSO-d6, ppm): δ = 38.4, 101.2, 127.0, 128.9,  
129.6, 130.7, 162.3, 170.7. ppm; MS (Cl): m/z 
411 (MH+ 100). Anal calcd. for C20H18N4O4S: 
C, 58.53, H, 4.42, N, 13.65, S, 7.81. Found: C, 
58.55, H, 4.41, N, 13.63, S, 7.84. 
N, N'-bis {[3- (4-methoxyphenyl) 
isoxazol-5-yl] methyl} sulfamide (3b) 
Colourless solid (77% yield); Mp: 167-168 oC. 
1H NMR (500 MHz, DMSO-d6): δ = 3.75-3.87 
(br. S, 6H), 4.17-4.29 (br. S, 4H), 6.76-6.88 (br. 
S, 2H), 7.02 (d, J=11.5  Hz, 4H), 7.75 (d, J 
=11.5  Hz, 4H), 7.83-98 (m, 2H). 13C NMR (125 
MHz, DMSO-d6, ppm): δ =  38.4, 55.7, 100.9, 
114.9, 128.5, 121.3, 161.2, 161.9, 170.3. ppm; 
MS (Cl): m/z 471 (MH+ 100). Anal calcd. for 
C22H22N4O6S: C, 56.16, H, 4.71, N, 11.91, S, 
6.82. Found: C, 56.12, H, 4.74, N, 11.90, S, 
6.82. 
 N, N'-bis {[3- (4-ethoxyphenyl) 
isoxazol-5-yl] methyl} sulfamide (3c) Colourless 
solid (79% yield); Mp: 164-165 oC.  1H NMR 
(500 MHz, DMSO-d6): δ = 1.34 (t, J= 8.5 Hz, 
6H), 4.06 (k, J=8.5 Hz, 4H), 4.15-4.88 (br S, 
4H), 6.83 (S, 2H), 6.97 (d, J=11.0 Hz, 4H), 7.73 
(d, J=11.0 Hz, 4H), 7.84-7.95 (m, 2H).  13C 
NMR (125 MHz, DMSO-d6, ppm): δ = 15.1, 
38.5, 63.7, 100.9, 115.4, 121.2, 128.5, 160.4, 
160.9, 170.3 ppm; MS (Cl): m/z 499 (MH+ 100). 
Anal calcd. for C24H26N4O6S: C, 57.82, H, 5.26, 
N, 11.24, S, 6.43. Found: C, 57.80, H, 5.25, N, 
11.26, S, 6.45. 
 N, N'-bis {[3- (4-propoxyphenyl) 
isoxazol-5-yl] methyl} sulfamide (3d) 
Colourless solid (72% yield); Mp: 159-160 oC.  
1H NMR (500 MHz, DMSO-d6): δ = 0.98 (t, J= 
8.5 Hz, 6H),1.67-1.79 (m, 4H) 3.96 (t, J=8.5 
Hz, 4H), 4.20-4.28 (br S, 4H), 6.83 (S, 2H), 
7.00 (d, J=11.0 Hz, 4H), 7.73 (d, J=11.0 Hz, 
4H), 7.88-7.96 (m, 2H).  13C NMR (125 MHz, 
DMSO-d6, ppm): δ = 10.8, 22.5, 38.5, 69.6, 
100.9, 115.4, 121.2, 128.5, 160.6, 160.9, 170.3 
ppm; MS (Cl): m/z 526 (MH+ 100). Anal calcd. 
for C26H30N4O6S: C, 59.30, H, 5.74, N, 10.64, 
S, 6.09. Found: C, 59.25, H, 5.71, N, 10.66, S, 
6.12. 
General procedure for the synthesis of 
for N,N'-diallyl-bis[(3-arylisoxazol-5-
yl)methyl]sulfamides: To the mixture (0.005 
mol) of corresponding sulfamides (3a-d) and 
(0.011 mol) potassium carbonate in 20 ml 
DMFA (0.015 mol) of allyl bromide was added. 
The reaction mixture is stired at a temperature 
of 65-70 oC for 4-5 hours. The solvent was  
removed in vacuo, the residue was washed with 
water, the product was extracted with 2 x 15 ml 
of dichloromethane. The extract was dried with 
anhydrous sodium sulfate and after purification 
by chromatography (silica gel Merck Grade 
9385, 60 A, 230-400, dichloromethane eluent) 
by evaporation of the solvent and subsesequent 
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recrystallization from 70% aqueous ethanol, the 
product was isolated. 
N,N'-diallyl-bis[(3-phenylisoxazol-5-
yl)methyl]sulfamide (4a) Colourless solid (91% 
yield); Mp: 129-130 oC.  1H NMR (500 MHz, 
CDCl3): δ = 3.86 (d, J=7.5 Hz, 4H), 4.54 (s, 
4H), 5.26-5.37 (m, 4H), 5.78-5.91 (m, 2H), 6.60 
(s, 2H), 7.73 (br. S, 6H), 7.77 (br. S, 4H). 13C 
NMR (125 MHz, CDCl3, ppm): δ = 42.0, 50.5, 
102.0, 120.7, 126.8, 128.7, 128.9, 130.2, 131.8, 
162.6, 168.2. ppm; MS (Cl): m/z 490 (MH+ 
100). Anal calcd. for C26H26N4O4S: C, 63.66, H, 
5.34, N, 11.42, S, 6.54. Found: C, 63.46, H, 
5.40, N, 11.48, S, 6.58. 
N,N'-diallyl-N,N'-bis{[(3-(4-
methoxyphenylisoxazol-5-yl)methyl]}sulfamide 
(4b) Colourless solid (88% yield); Mp: 108-109 
oC.  1H NMR (500 MHz, DMSO-d6, ppm): δ = 
3.29-3.36 (br s,4H), 3.82-3.3.90 (br.s, 6H), 4.46-
4.60 (br. s, 4H), 5.19-5.37 (m, 4H), 5.75-5.89 
(m, 2H), 6.93 (br. s, 2H), 7.04 (d, J= 10.5 Hz, 
4H), 7.78 (d, J=10.5 Hz, 4H). 13C NMR (125 
MHz, DMSO-d6), ppm): δ = 42.7, 51.1, 55.8, 
102.1, 115.0, 120.2, 121.2, 128.6, 133.0, 161.2, 
162.0, 169.0. ppm; MS (Cl): m/z 550 (MH+ 
100). Anal calcd. for C28H30N4O6S: C, 61.08, H, 
5.49, N, 10.18, S, 5.82. Found: C, 61.10, H, 
5.45, N, 10.19, S, 5.88.  
N,N'-diallyl-N,N'-bis{[(3-(4-
ethoxyphenylisoxazol-5-yl)methyl]}sulfamide 
(4c) Colourless solid (81% yield); Mp: 104-105 
oC.  1H NMR (500 MHz, CDCl3): δ = 1.44 (t, J= 
8.5 Hz, 6H), 3.85 (d, J=8.0 Hz, 4H), 4.07 (k, 
J=8.5, 4H), 4.50 (s, 4H), 5.24-5.37 (m,4H), 
5.77-5.90 (m, 2H), 6.52 (s, 2H), 6.93 (d, J= 10.5 
Hz, 4H), 7.70 (d, J=10.5 Hz, 4H). 13C NMR 
(125 MHz, CDCl3, ppm): δ = 14.8, 41.9, 50.8, 
63.6, 101.6, 114.8, 120.6, 120.9, 128.2, 131.8, 
160.6, 162.2, 167.8. ppm; MS (Cl): m/z 578 
(MH+ 100). Anal calcd. for C30H34N4O6S: C, 
62.27, H, 5.92, N, 9.68, S, 5.54. Found: C, 
62.25, H, 5.88, N, 9.70, S, 5.57.  
N,N'-diallyl-N,N'-bis{[(3-(4-
propoxyphenylisoxazol-5-yl)methyl]}sulfamide 
(4d) Colourless solid (75% yield); Mp: 99-100 
oC.  1H NMR (500 MHz, CDCl3): δ = 1.05 (t, 
J=8.0 Hz, 6H), 1.77-1.89 (m, 4H), 3.85 (d, 
J=8.0 Hz, 4H), 3.96 (t, J= 8.5, 4H), 4.51 (s, 4H), 
5.25-5.35 (m, 4H), 5.76-5.91 (m, 2H), 6.52 (s, 
2H), 6.93 (d, J= 11.0 Hz, 4H), 7.70 (d, J=11.0 
Hz, 4H). 13C NMR (125 MHz, CDCl3, ppm): δ = 
10.5, 22.5, 42.0, 50.9, 69.6, 101.6, 114.9, 120.6, 
120.9, 128.2, 131.9, 160.7, 162.3, 167.9. ppm; 
MS (Cl): m/z 606 (MH+ 100). Anal calcd. for 
C32H38N4O6S: C, 63.35, H, 6.31, N, 9.23, S, 
5.28. Found: C, 63.32, H, 6.28, N, 9.26, S, 5.30.  
General procedure for the synthesis of 
for 2,7-bis[(3-arylisoxazol-5-yl)methyl]-2,3,6,7-
thiadiazepine 1,1-dioxides: To a solution (0.6 
mmol) of сorresponding diallyl derivatives 4a-d 
in 15 ml of dry degassed dichloromethane in a 
dry argon atmosphere (0.028-0.03 mmol, 
5%mole) catalyst [Ru] was added. The mixture 
was kept at room temperature for 10-12 hours. 
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After completion of the reaction, the target 
products were isolated from the reaction 
mixture by colum chromatography (Merck 
Grade 9385, 60 A, 230-400, dichloromethane) 
followed by evaporation and recrystallization of 
the products from 70% aqueous ethanol. 
2,7-bis[(3-phenylisoxazol-5-
yl)methyl}2,3,6,7-tetrahydro-1,2,7-thiadiazepine 
1,1-dioxide (5a). Colourless solid (91% yield); 
Mp: 134-135 oC.  1H NMR (500 MHz, CDCl3): 
δ = 3.91 (s, 4H), 4.62 (s, 4H), 5.84 (s, 2H), 6.65 
(s, 2H), 7.45 (s, 6H), 7.80 (d, J= 4.5 Hz, 4H). 
13C NMR (125 MHz, CDCl3, ppm): δ = 44.8, 
45.3, 101.5, 126.8, 128.2, 128.7, 129.0, 130.2, 
162.7, 168.2. ppm; MS (Cl): m/z 463 (MH+ 
100). Anal calcd. for C24H22N4O4S: C, 62.32, H, 
4.79, N, 12.11, S, 6.93. Found: C, 62.30, H, 
4.77, N, 12.14, S, 6.94. 
2,7-bis{[3-(4-methoxyphenyl)isoxazol-5-
yl]methyl}-2,3,6,7-tetrahydro-1,2,7-
thiadiazepine 1,1-dioxide (5b) Colourless solid 
(85% yield); Mp: 139-140 oC.  1H NMR (500 
MHz, CDCl3): δ = 3.85 (s, 6H), 3.90 (s, 4H), 
4.60 (s, 4H), 5.84 (s, 2H), 6.58 (s, 2H), 6.97 (d, 
J= 11.0 Hz, 6H), 7.73 (d, J= 11.0 Hz, 4H). 13C 
NMR (125 MHz, CDCl3, ppm): δ = 44.7, 45.2, 
55.4, 101.2, 114.4, 121.1, 128.2, 161.2, 162.3, 
168.1. ppm; MS (Cl): m/z 523(MH+ 100). Anal 
calcd. for C26H26N4O6S: C, 59.76, H, 5.01, N, 
10.72, S, 6.14. Found: C, 59.80, H, 5.03, N, 
10.68, S, 6.15. 
2,7-bis{[3-(4-ethoxyphenyl)isoxazol-5-
yl]methyl}-2,3,6,7-tetrahydro-1,2,7-
thiadiazepine 1,1-dioxide (5c) Colourless solid 
(82% yield); Mp: 129-130 oC.  1H NMR (500 
MHz, CDCl3): δ = 1.44 (t, J= 8.5 Hz, 6H), 3.90 
(s, 4H), 4.07 (k, J= 8.5 Hz, 4H), 4.59 (s, 4H), 
5.84 (s, 2H), 6.58 (s, 2H), 6.95 (d, J= 11.0 Hz, 
4H), 7.72 (d, J= 11.0 Hz, 4H). 13C NMR (125 
MHz, CDCl3, ppm): δ = 14.7, 44.7, 45.2, 63.6, 
101.2, 114.9, 120.9, 128.2, 160.5, 162.4, 168.1. 
ppm; MS (Cl): m/z 551 (MH+ 100). Anal calcd. 
for C28H30N4O6S: C, 61.08, H, 5.49, N, 10.18, 
O, 17.43, S, 5.82. Found: C, 61.05, H, 5.45, N, 
10.20, O, 17.46, S, 5.84. 
2,7-bis{[3-(4-propoxyphenyl)isoxazol-5-
yl]methyl}-2,3,6,7-tetrahydro-1,2,7-
thiadiazepine 1,1-dioxide (5d) Colourless solid 
(86% yield); Mp: 125-126 oC.  1H NMR (500 
MHz, CDCl3): δ = 1.05 (t, J= 9.0 Hz, 6H), 1.77-
1.89 (m, 4H), 3.91 (s, 4H), 3.97 (t, J= 8.0 Hz, 
4H), 4.60 (s, 4H), 5.84 (s, 2H), 6.58 (s, 2H), 
6.96 (d, J= 10.5 Hz, 4H), 7.72 (d, J= 10.5 Hz, 
4H). 13C NMR (125 MHz, CDCl3, ppm): δ = 
10.5, 22.5, 44.7, 45.2, 69.6, 101.2, 114.9, 120.2, 
128.2, 128.3, 160.8, 162.4, 168.0. ppm; MS 
(Cl): m/z 579 (MH+ 100). Anal calcd. for 
C30H34N4O6S: C, 62.27, H, 5.92, N, 9.68, S, 
5.54. Found: C, 62.24, H, 5.95, N, 9.65, S, 5.56. 
Conclusions 
Thus, with the help of ring-closing 
metathesis reactions some of new  potentially 
biologically  active isoxazole-containing 
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2019, VOLUME 07, ISSUE 01)  
111 
 
derivatives of the thiadiazepine series were 
synthesited. The comfortable synthetic sequence 
was worked out and the principle possibility of 
obtaining the symmetric isoxasole containing 
derivatives of thiadiazepine was established. 
The structure of the obtained substances was 
confirmed by chromatomass spectra, elemental 
analysis and data of 1H, 13C   NMR  
spectroscopy. 
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